Development and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules - 11/09/11
Abstract |
OBJECTIVE: We initiated studies to develop cytokine-secreting human ovarian carcinoma cells for the purpose of using these cells as vaccines for the treatment of advanced epithelial ovarian cancer. STUDY DESIGN: A human ovarian carcinoma cell line (UCI-107) was genetically engineered to secrete the cytokine interleukin-2 by retroviral-mediated gene transduction. RESULTS: One clone, termed UCI-107A IL-2 AS, constitutively secreted high levels of interleukin-2 (i.e., 2000 to 2300 pg/ml/105 cells per 48 hours) for >55 passages and 8 months of study. Unlike parental- and vector-transduced cells, UCI-107A IL-2 AS cells were aneuploid and failed to express major histocompatibility complex class I and HER2/neu surface antigens. UCI-107A IL-2 AS cells were highly resistant to killing by gamma irradiation and continued to produce high levels of interleukin-2 even after irradiation with 10,000 cGy. Balb/C nude mice injected intraperitoneally with UCI-107A IL-2 AS cells survived significantly longer than control animals, with 25% of the animals totally rejecting their tumors. UCI-107A IL-2 AS was totally resistant to killing by fresh allogeneic peripheral blood lymphocytes in four hour chromium 51 release assays but induced high levels of killing in 72-hour long-term cytotoxic assays. CONCLUSION: The potential use of these interleukin-2 - secreting ovarian carcinoma cells as vaccines for women with advanced ovarian cancer will be discussed. (AM J OBSTET GYNECOL 1996;174:633-40.)
Le texte complet de cet article est disponible en PDF.Keywords : Interleukin-2, ovarian cancer, tumor vaccine
Plan
| ☆ | From the Department of Molecular Biology and Biochemistry, University of California, Irvine,a the Divisions of Gynecologic Oncologyb and Pathology,c University of California, Irvine Medical Center, the Division of Gynecologic Oncology, University of Brescia,d and the Memorial Cancer Institute, Long Beach Memorial Medical Center.e |
| ☆☆ | Supported in part by grants from Memorial Health Services of Long Beach Memorial Medical Center, Long Beach, California, Oncotech, Irvine, California, the Schmidt Foundation of Irvine, California, and the Camillo Golgi Foundation, Brescia, Italy. |
| ★ | Reprint requests: Gale A. Granger, PhD, Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA 92717-3900. |
| ★★ | 0002-9378/96 $5.00 + 0 6/1/67415 |
Vol 174 - N° 2
P. 633-640 - février 1996 Retour au numéro
Article précédent
- Smoking and cycle control among oral contraceptive users
- Michael J. Rosenberg, Michael S. Waugh, Catherine M. Stevens
- Ovarian remnant syndrome: Experience at Jackson Memorial Hospital, University of Miami, 1985 through 1993
- Heather W. Lafferty, Roberto Angioli, Jane Rudolph, Manuel A. Penalver
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?